Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts

International Journal of Oncology

Volumn 28, Issue 4, 2006, Pages 855-861

  Li, Li ^a   Giannopoulos, Krzysztof ^a,d   Reinhardt, Peter ^b   Tabarkiewicz, Jacek ^d   Schmitt, Anita ^b   Greiner, Jochen ^a   Rolinski, Jacek ^d   Hus, Iwona ^c   Dmoszynska, Anna ^c   Wiesneth, Markus ^b   Schmitt, Michael ^a  

^a UNIVERSITY OF ULM   (Germany)

^b German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

^c Department of Hematooncology ^*  (Poland)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Acute myeloid leukemia; Dendritic cells; Leukemia associated antigen

Indexed keywords

CD83 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GRANZYME; GZMB PROTEIN, HUMAN; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; PRAME PROTEIN, HUMAN; SERINE PROTEINASE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ADOPTIVE IMMUNOTHERAPY; AGED; ARTICLE; AUTOTRANSPLANTATION; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOLOGY; MALE; METHODOLOGY; MIDDLE AGED; MONONUCLEAR CELL; MULTICENTER STUDY; MYELOID LEUKEMIA; PATHOLOGY; TIME; TRANSPLANTATION; TREATMENT OUTCOME; VACCINATION;

ACUTE DISEASE; AGED; ANTIGENS, CD; ANTIGENS, CD86; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GRANZYMES; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY, ADOPTIVE; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-5; LEUKEMIA, MYELOID; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; SERINE ENDOPEPTIDASES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 33744736610     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.4.855     Document Type: Article

References (32)

1. Stone RM, O'Donnell MR and Sekeres MA: Acute myeloid leukemia. (ASH Educ Program). Hematology: 98-117, 2004.
2. Banchereau J, Brière F, Caux C, Davoust J, Lebecque S, Liu YJ and Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811, 2000.
3. Banchereau J, Schuler-Thurner B, Palucka AK and Schuler G: Dendritic cells as vectors for therapy. Cell 106: 271-274, 2001.
4. Hus I, Rolinski J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, Giannopoulos K, Dmoszynska A and Schmitt M: Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early stage B-cell chronic lymphocytic leukemia (B-CLL). Leukemia (In press).
5. + acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 94: 2048-2055, 1999.
6. Kohler T, Plettig R, Wetzstein W, Schmitz M, Ritter M, Mohr B, Schaekel U, Ehninger G and Bornhäuser M: Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells 18: 139-147, 2000.
7. Choudhury A, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE and Claxton DF: Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous antileukemic T cell responses. Blood 93: 780-786, 1999.
8. Li L, Reinhardt P, Schmitt A, Barth TF, Greiner J, Ringhoffer M, Döhner H, Wiesneth M and Schmitt M: Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol Immunother 54: 685-693, 2005.
9. Li L, Schmitt A, Reinhardt P, Greiner J, Ringhoffer M, Vaida B, Bommer M, Vollmer M, Wiesneth M, Döhner H and Schmitt M: Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Cancer Immun 3: 8, 2003.
10. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, De Smet C, Chambost H, Vitale M, Moretta A, Boon T and Coulie PG: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6: 199-208, 1997.
11. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K, Kishimoto T and Sugiyama H: Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 164: 1873-1880, 2000.
12. Charbonnier A, Gaugler B, Sainty D, Lafage-Pochitaloff M and Olive D: Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. Eur J Immunol 29: 2567-2578, 1999.
13. Stripecke R, Levine AM, Pullarkat V and Cardoso AA: Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia 16: 1974-1983, 2002.
14. Woiciechowsky A, Regn S, Kolb H-I and Roskrow M: Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia 15: 246-255, 2001.
15. Kufner S, Fleischer RP, Kroell T, Schmid C, Zitzelsberger H, Salih H, Valle FD, Treder W and Schmetzer HM: Serum-free generation and quantification of functionally active leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol Immunother, 2005 E-pub ahead of print.
16. Klammer M, Waterfall M, Samuel K, Turner ML and Roddie PH: Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Br J Haematol 129: 340-349, 2005.
17. Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos K, Guillaume P, Ritter G, Wiesneth M, Döhner H and Schmitt M: Identification and characterization of epitopes of the receptor for hyaluronic acid mediated motility (RHAMM/CD168) recognized by CD8 positive T cells of HLA-A2 positive patients with acute myeloid leukemia. Blood 106: 938-945, 2005.
18. Margolis J, Borrello I and Flinn IW: New approaches to treating malignancies with stem cell transplantation. Semin Oncol 27: 524-530, 2000.
19. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW and Keilholz U: Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18: 165-166, 2004.
20. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I and Sugiyama H: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101: 13885-13890, 2004.
21. Vollmer M, Li L, Schmitt A, Greiner J, Reinhardt P, Ringhoffer M, Wiesneth M, Döhner H and Schmitt M: Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia. Br J Haematol 120: 1000-1008, 2003.
22. Dunussi-Joannopoulos K, Weinstein HJ, Arceci RJ and Croop JM: Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model. J Pediatr Hematol Oncol 19: 536-540, 1997.
23. Hsu FJ, Benike C, Fagnoti F, Liles TM, Czerwinski D, Taidi B, Engelman EG and Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52-58, 1996.
24. Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, Audring H, Guo Y, Sterry W and Walden P: Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer 85: 618-626, 2000.
25. Su Z, Dannull J, Heiser A, Yansey D, Pruitt S, Madden J, Coleman D, Niedzwicki D, Gilboa E and Vieweg J: Immunological and clinical responses in metastatic renal cancer patients with tumor-RNA-transfected dendritic cells. Cancer Res 63: 2127-2133, 2003.
26. Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K and Murai M: Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 7: 23-31, 2001.
27. Rasmussen T, Hansson L, Osterborg A, Johnsen HE and Mellstedt H: Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 101: 4607-4610, 2003.
28. Ruffini PA, Neelapu SS, Kwak L and Biragyn A: Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 87: 989-1001, 2002.
29. Lee JJ, Kook H, Park MS, Nam JH, Choi BH, Song WH, Park KS, Lee IK, Chung IJ, Hwang TJ and Kim HJ: Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apheresis 19: 66-70, 2004.
30. Russell JH and Ley TJ: Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20: 323-370, 2002.
31. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D and Levitsky H: The central role of CD4 (+) T cells in the antitumor immune response. J Exp Med 188: 2357-2368, 1998.
32. Klinman DM, Currie D, Gursel I and Verthelyi D: Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 199: 201-216, 2004.